THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2022

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2022-10-01 to 2023-09-30
Filed: 2024-08-06
IRS object ID: 202432199349301603
Schema version: 2022v5.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2024-08-06T12:14:10-05:00	ReturnTs
Tax Period End	2023-09-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	873231666	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	PKF O'CONNOR DAVIES ADVISORY LLC	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	500 MAMARONECK AVENUE SUITE 301	AddressLine1Txt
City	HARRISON	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	105281633	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2022-10-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	FOUN	BusinessNameControlTxt
Phone	2128061600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	BRADLEY JENSEN	PersonNm
Person Title	ASST TREASURER & CFO	PersonTitleTxt
Phone	2128061600	PhoneNum
Signature	2024-08-06	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	Yes (1)	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	GARRETT M HIGGINS	PreparerPersonNm
PTIN	P00543209	PTIN
Phone	9143818900	PhoneNum
Preparation	2024-07-31	PreparationDt

Field	Value	IRS element (for citing)
Tax	2022	TaxYr
Build TS	2024-08-08 14:25:15Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	AIDS RESEARCH FOUNDATION	BusinessNameLine1Txt
Business Name Line2	AMFAR	BusinessNameLine2Txt

Field	Value	IRS element (for citing)
Principal Officer	KEVIN FROST	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$50,922,303	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.AMFAR.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1983	FormationYr
Legal Domicile State	NY	LegalDomicileStateCd
Activity Or Mission	AFMAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. (SEE SCHEDULE O)	ActivityOrMissionDesc
Voting Members Governing Body	14	VotingMembersGoverningBodyCnt
Voting Members Independent	14	VotingMembersIndependentCnt
Total Employee	79	TotalEmployeeCnt
Total Volunteers	23	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$43,792,707	PYContributionsGrantsAmt
CY Contributions Grants	$42,216,134	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$765,179	PYInvestmentIncomeAmt
CY Investment Income	$906,419	CYInvestmentIncomeAmt
PY Other Revenue	-$13,113,741	PYOtherRevenueAmt
CY Other Revenue	-$14,039,846	CYOtherRevenueAmt
PY Total Revenue	$31,444,145	PYTotalRevenueAmt
CY Total Revenue	$29,082,707	CYTotalRevenueAmt
PY Grants And Similar Paid	$3,480,627	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$5,747,152	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$11,385,131	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$11,557,110	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$556,416	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$525,768	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$6,522,246	CYTotalFundraisingExpenseAmt
PY Other Expenses	$12,581,968	PYOtherExpensesAmt
CY Other Expenses	$16,110,216	CYOtherExpensesAmt
PY Total Expenses	$28,004,142	PYTotalExpensesAmt
CY Total Expenses	$33,940,246	CYTotalExpensesAmt
PY Revenues Less Expenses	$3,440,003	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$4,857,539	CYRevenuesLessExpensesAmt
Total Assets BOY	$55,186,037	TotalAssetsBOYAmt
Total Assets EOY	$50,719,163	TotalAssetsEOYAmt
Total Liabilities BOY	$20,091,685	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$18,349,538	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$35,094,352	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$32,369,625	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SEE SCHEDULE O	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$13,557,689	ExpenseAmt
Grant	$3,874,168	GrantAmt
Revenue	$0	RevenueAmt
Desc	AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS. FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEULE O.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$5,074,670	ExpenseAmt
Grant	$1,734,984	GrantAmt
Revenue	$0	RevenueAmt
Desc	TREAT ASIAFOR MORE THAN 20 YEARS, AMFAR'S TREAT ASIA PROGRAM (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) HAS BEEN WORKING WITH PARTNERS ACROSS THE ASIA-PACIFIC REGION TO EXPAND ACCESS TO TREATMENT FOR HIV AND RELATED CONDITIONS SUCH AS HEPATITIS C (HCV) AND IMPROVE STANDARDS OF CARE. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 21 PEDIATRIC SITES IN 12 COUNTRIES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. TREAT ASIA SCIENTISTS PUBLISHED 25 PAPERS IN PEER-REVIEWED MEDICAL JOURNALS IN FY2023. TREAT ASIA AND NETWORK PARTNER RESEARCHTREAT ASIA AND ITS NETWORK PARTNERS CONDUCT NUMEROUS STUDIES, WHICH THIS YEAR INCLUDED RESEARCH ON LONG-TERM TREATMENT OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV, PREGNANCY OUTCOMES AMONG WOMEN LIVING WITH HIV, LUNG CANCER, LUNG IMPAIRMENT IN HIV AND TB, MENTAL HEALTH SCREENING AND LINKAGE TO CARE STRATEGIES, THE VIRAL HEPATITIS CASCADE OF CARE, SEROLOGY OF SARS-COV-2 AND OTHER VIRAL PATHOGENS, CHEMSEX IN YOUNG MEN WHO HAVE SEX WITH MEN (MSM), TB PREVENTIVE THERAPY, AND HPV AND ANAL CANCER RISK AMONG MSM, AMONG OTHERS. INTERNATIONAL AIDS DATABASETREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IEDEA IS CENTRAL TO A WIDE RANGE OF INTERNATIONAL STUDIES, LISTED BELOW, IN WHICH TREAT ASIA PARTICIPATES.IEDEA DOLUTEGRAVIR RESISTANCE STUDYTHIS GLOBAL STUDY LED BY THE UNIVERSITY OF BERN AIMS TO DETERMINE PATTERNS AND RISK FACTORS FOR VIROLOGIC FAILURE IN ADULTS ON DOLUTEGRAVIR (DTG)-BASED ART, AND TO INVESTIGATE CORRELATIONS BETWEEN RESISTANCE GENOTYPES ACROSS HIV-1 SUBTYPES. THE STUDY IS ONGOING IN THREE IEDEA ASIA-PACIFIC NETWORK SITES IN CAMBODIA (1) AND THAILAND (2). IEDEA TUBERCULOSIS SENTINEL RESEARCH NETWORK (IEDEA TB-SRN): THE GLOBAL STUDY AIMS TO DESCRIBE CLINICAL AND TREATMENT OUTCOMES OF PULMONARY TB AND PROVIDE A PLATFORM FOR GLOBAL TB RESEARCH AMONG PEOPLE WITH AND WITHOUT HIV. THREE IEDEA ASIA-PACIFIC SITES ARE PARTICIPATING: NCHADS (KAMPONG CHAM HOSPITAL), CAMBODIA, AND NATIONAL HOSPITAL OF TROPICAL DISEASES (NHTD) AND NATIONAL HOSPITAL 74, VIETNAM. IEDEA SENTINEL RESEARCH NETWORK (IEDEA SRN): THE GLOBAL STUDY IS ASSESSING LIVER, CARDIO-METABOLIC, MENTAL HEALTH, AND SUBSTANCE USE COMORBIDITIES AMONG PEOPLE WITH HIV OVER 40 YEARS OF AGE, ON ART FOR MORE THAN SIX MONTHS. IT IS BEING IMPLEMENTED AT TWO IEDEA ASIA-PACIFIC SITES: BJ MEDICAL COLLEGE IN PUNE, INDIA, AND NATIONAL HOSPITAL OF TROPICAL DISEASES IN HANOI, VIETNAM. THE SOUTHEAST ASIA TRANSGENDER COHORT STUDY (SEATRANS): THE REGIONAL PROSPECTIVE COHORT STUDY WILL ENROLL 450 TRANSGENDER PARTICIPANTS WITH AND WITHOUT HIV ACROSS FOUR SITES IN THE PHILIPPINES, THAILAND AND VIETNAM TO 1) TRACK PHYSICAL AND MENTAL HEALTH AMONG TRANSGENDER PEOPLE; 2) IDENTIFY BIOMEDICAL, STRUCTURAL, AND PSYCHOSOCIAL FACTORS IMPACTING PHYSICAL AND MENTAL HEALTH; 3) DESCRIBE STRUCTURAL BARRIERS TO HEALTHCARE; AND 4) DEVELOP GUIDANCE ON HOLISTIC HEALTHCARE POLICIES FOR TRANSGENDER PEOPLE. SUICIDAL BEHAVIOR AMONG THAI ADOLESCENTS LIVING WITH HIV (S-BETAH): THIS PROSPECTIVE COHORT STUDY AIMS TO DETERMINE THE PREVALENCE OF MENTAL HEALTH DISORDERS AND SUICIDAL BEHAVIOR FOLLOWING POSITIVE SCREENING AND LINKAGE TO MENTAL HEALTH SERVICES. WITH THE FIRST PHASE COMPLETED, THE SECOND PHASE WILL ASSESS THE PREVALENCE AND INCIDENCE OF SUICIDALITY AMONG THIS POPULATION COMPARED WITH THEIR HIV-NEGATIVE AGE- AND SEX-MATCHED COUNTERPARTS. FACTORS ASSOCIATED WITH SUICIDALITY ALSO WILL BE IDENTIFIED.THE MENTAL HEALTH AND HIV SERVICE INTEGRATION (MHINT) STUDY: THIS MIXED METHODS IMPLEMENTATION-EFFECTIVENESS HYBRID STUDY LED BY TREAT ASIA IN COLLABORATION WITH COLUMBIA UNIVERSITY WILL BE IMPLEMENTED AT FOUR PARTICIPATING SITES [BANGKOK (2), MANILA, AND KUALA LUMPUR] WITH THE AIM OF DEVELOPING AND ASSESSING MENTAL HEALTH SCREENING AND LINKAGE TO CARE STRATEGIES.HEPATITIS C VIRUS COINFECTIONDRAWING ON DATA FROM ONE OF TREAT ASIA'S OBSERVATIONAL DATABASES, AN ONGOING STUDY IS INVESTIGATING TRENDS IN HEPATITIS C VIRUS COINFECTION AND ITS CASCADE OF CARE AMONG ADULTS LIVING WITH HIV IN ASIA FROM 2010 TO 2020.INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCHIN 2019, THE U.S. NIH AWARDED A FIVE-YEAR, $1.4 MILLION GRANT TO TREAT ASIA AND COLUMBIA UNIVERSITY TO ESTABLISH AN INNOVATIVE PLATFORM FOR INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN THE ASIA-PACIFIC REGION. THE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG OF COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE CLINICAL CARE FOR PEOPLE LIVING WITH HIV. CHIMERA CREATES THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND BUILDS ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC. SIX FELLOWS PARTICIPATED IN THE ASIA-PACIFIC AIDS & CO-INFECTIONS CONFERENCE IN SINGAPORE IN JUNE, AND TWO CLASS 1 FELLOWS PRESENTED E-POSTERS AT THE 12TH IAS CONFERENCE ON HIV SCIENCE IN AUSTRALIA IN JULY. THROUGHOUT THE YEAR, FELLOWS CONTINUED IMPLEMENTATION OF THEIR PILOT RESEARCH PROJECTS, WITH MAJOR STRIDES MADE IN DATA COLLECTION, DATA CODING, AND PRELIMINARY ANALYSIS. IMPROVING HEALTH THROUGH INFORMATIONTREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)TREAT ASIA PIONEERED THE REGION'S FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH INCLUDED ANONYMOUS DATA FROM MORE THAN 10,700 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES IN ITS FINAL DATA TRANSFER IN SEPTEMBER 2021. TAHOD TRANSITIONED TO THE TAHOD CONTINUUM OF CARE (TAHOD-CC) COHORT IN 2022 AND CONTINUED ITS DATA TRANSFERS THROUGHOUT 2023. THE INFORMATION GATHERED IN THE DATABASES HAS INFORMED THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPED DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. A REPORT, "HIV TREATMENT OUTCOMES AFTER 10 YEARS ON ART IN THE TREAT ASIA OBSERVATIONAL DATABASE (TAHOD) AND AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD)," WAS PRESENTED AT BOTH APACC 2023 AND IAS 2023.TAHOD LOW-INTENSITY TRANSFER LAUNCHED IN 2014, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINED DATA FROM OVER 51,000 HIV-POSITIVE PATIENTS ACROSS 11 TREAT ASIA NETWORK SITES IN ITS FINAL DATA TRANSFER IN 2021. ANALYSIS CONTINUED THROUGH FY2023. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF PEOPLE LIVING WITH HIV WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES.TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 7,500 CHILDREN AND ADOLESCENTS AT 21 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM.COMMUNITY-LED MONITORING DASHBOARDWITH THE HELP OF AMFAR'S PUBLIC POLICY OFFICE AND ALONG WITH COMMUNITY NETWORK FOR EMPOWERMENT (CONE) IN MANIPUR, INDIA, AND PEDULI HATI IN INDONESIA, TREAT ASIA DEVELOPED AN ONLINE DASHBOARD (WWW.CLM-ASIA.ORG) TO EXPAND AND ENHANCE COMMUNITY-LED MONITORING IN THE IMPLEMENTING ORGANIZATIONS' RESPECTIVE COUNTRY REGIONS. THE DASHBOARD IS SUPPORTED IN PART BY VIIV HEALTHCARE.RESPONDING TO COVID-19 TREAT ASIA CONTINUED TO COLLATE DATA ABOUT ADULTS AND CHILDREN IMPACTED BY COVID-19. COVID-19 DATA ON NEARLY 600 CASES WERE TRANSFERRED TO TAHOD BY EIGHT PARTICIPATING SITES IN LATE 2021. AN ANALYSIS ON COVID-19 CLINICAL PRESENTATIONS AND OUTCOMES AMONG PLHIV IS BEING CONDUCTED. FOR THE PEDIATRIC DATABASE, 11 SITES ARE PARTICIPATING IN COVID-19 DATA COLLECTION: CAMBODIA (1), INDIA (2), INDONESIA (3), MALAYSIA (1), THAILAND (1) AND VIETNAM (3). TO DATE, DATA ON 454 PEDIATRIC COVID-19 CASES HAVE BEEN TRANSFERRED TO THE KIRBY INSTITUTE, AND A CONCEPT SHEET TO ANALYZE THE DATA HAS BEEN DEVELOPED. LAUNCHED IN 2021, TREAT ASIA'S COVID WEBSITE - WWW.COVID19ASIAINFO.ORG - CONTINUED TO BE AN IMPORTANT SOURCE OF INFORMATION ON COVID VACCINES AND THERAPEUTICS RELEVANT TO THE ASIA-PACIFIC REGION.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$3,820,815	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	PUBLIC INFORMATIONAMFAR TRANSLATES AND DISSEMINATES INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION AND TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. EDUCATIONAL MATERIALS AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND DIGITAL FORMATS, INCLUDING ITS NEWSLETTER, INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO ABOUT 16,000 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER, INSIGHTS, DISTRIBUTED TO APPROXIMATELY 20,000 RECIPIENTS. THE FOUNDATION'S WEBSITE - WWW.AMFAR.ORG - FEATURES NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITE ATTRACTS AN AVERAGE OF 18,000 VISITS AND OVER 31,000 PAGEVIEWS PER MONTH. AMFAR CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE AND TREAT ASIA STAFF (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.SOCIAL MEDIAAMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. POSTS IN FY2023 COVERED TOPICS SUCH AS TREATMENT ACCESS, HIV CRIMINALIZATION (INCLUDING UGANDA'S ANTI-HOMOSEXUALITY ACT), CUTS IN HIV FUNDING, THE IMPORTANCE OF HIV TESTING, WOMEN'S HEALTH, AND THE ACCOMPLISHMENTS OF PEPFAR ON THE GLOBAL HEALTH PROGRAM'S TWENTIETH ANNIVERSARY AND IN LIGHT OF ITS POSSIBLE DEFUNDING BY CONGRESS. THE FOUNDATION HAS EXPANDED ITS SOCIAL PLATFORMS TO INCLUDE TIKTOK, TARGETING A NEW GENERATION OF ADVOCATES. AMFAR REGULARLY UPDATES ITS SOCIAL CHANNELS WITH THE LATEST RESEARCH BREAKTHROUGHS AND POLICY NEWS, AS WELL AS DETAILED COVERAGE FROM ITS WORLD-RENOWNED FUNDRAISING GALAS. AMFAR HAS OVER 85,000 FOLLOWERS ON FACEBOOK, MORE THAN 42,000 X (FORMERLY TWITTER) FOLLOWERS, OVER 120,500 TIKTOK FOLLOWERS, AND 194,000 INSTAGRAM FOLLOWERS. DURING AMFAR'S VENICE GALA, THE FOUNDATION'S INSTAGRAM POSTS GARNERED OVER 1.3M IMPRESSIONS THROUGH A COMBINATION OF PHOTO AND VIDEO CONTENT. AMFAR STRATEGICALLY PLACED SEVERAL PROGRAMMATIC MESSAGES IN ITS FEEDS THROUGHOUT THE EVENING TO CAPITALIZE ON HEIGHTENED TRAFFIC OUR CHANNELS RECEIVED. MEDIA OUTREACHAMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFAR MANY OF WHICH INCLUDED INTERVIEWS WITH STAFF WERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING NBC NEWS, PBS NEWSHOUR, NPR, ASSOCIATED PRESS, REUTERS, THE NEW YORK TIMES, THE WASHINGTON POST, THE GUARDIAN, THE OBSERVER, DALLAS MORNING NEWS, VANITY FAIR, VOGUE, VOGUE BUSINESS, W, PEOPLE, VARIETY, THE LANCET, PHARMACY TIMES, JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, POZ, AIDSMAP, THEBODY, CR FASHION BOOK, WOMEN'S WEAR DAILY, ELLE, US WEEKLY, THE HOLLYWOOD REPORTER, DEADLINE, PAGE SIX, WIRED, ET, ACCESS HOLLYWOOD, COSMOPOLITAN, TOWN & COUNTRY, CULTED, ARTNET, HAUTE LIVING, BUZZFEED, MIAMI LIVING, PALM BEACH DAILY NEWS, PALM BEACH SOCIETY, FLORIDA WEEKLY, THE TENNESSEAN, QUEST, ARTSPACE, GAY CITY NEWS, INSIDER, NYLON, VOGUE HONG KONG, HARPER'S BAZAAR FRANCE, EURONEWS, PARIS MATCH, L'OFFICIEL ITALIA, AND L'OFFICIEL AUSTRIA.AMFAR GARNERED APPROXIMATELY 21,400 MENTIONS ACROSS MEDIA IN FY2023.MULTIMODAL AWARENESS-RAISINGAMFAR FREQUENTLY SPOTLIGHTS AIDS AWARENESS NOT ONLY ACROSS DIFFERENT PLATFORMS BUT ACROSS DIFFERENT MEDIA IN ORDER TO REACH DIVERSE AUDIENCES. FOR WORLD AIDS DAY 2022, AMFAR'S PUBLIC INFORMATION TEAM PRODUCED A VIDEO FEATURING THE ORGANIZATION'S CEO AND PROGRAM HEADS, OFFERING INSIGHTS INTO PROGRESS ON HIV/AIDS, DOMESTIC AND FOREIGN HIV POLICY, AND CURRENT HIV RESEARCH.AMFAR PARTNERED WITH PROSPECT 100 TO SPONSOR AN NFT ART/DESIGN COMPETITION TO RAISE FUNDS FOR THE ORGANIZATION'S RESEARCH AND ADVOCACY PROGRAMS. JUDGES INCLUDED KENDALL JENNER, JEFF KOONS, KATE MOSS, J BALVIN, ALTON MASON, AND BAZ LUHRMANN.ALONG WITH MARKING NATIONAL HIV/AIDS AWARENESS DAYS THROUGHOUT THE YEAR, AMFAR HELPED COMMEMORATE THE 40TH ANNIVERSARY OF THE DENVER PRINCIPLES, A FOUNDING DOCUMENT THAT BECOME A BLUEPRINT OF EMPOWERMENT FOR PEOPLE LIVING WITH HIV/AIDS, WITH A WIDELY DISTRIBUTED PRESS RELEASE AND SOCIAL MEDIA POSTS.IN JUNE 2023, AMFAR ORGANIZED SEVERAL PRE-PRIDE EVENTS IN NEW YORK AND LOS ANGELES AND PARTICIPATED IN NEW YORK CITY'S HERITAGE OF PRIDE MARCH BY SPONSORING A FLOAT THAT CELEBRATED UNITY AND SOLIDARITY WITH THE LGBTQ+ COMMUNITY.BENEFIT EVENTSPUBLIC INFORMATION ASSISTED IN THE PRODUCTION OF BENEFIT EVENTS SUCH AS FUNDRAISING GALAS IN DALLAS, TEXAS, IN OCTOBER 2022; LOS ANGELES, CALIFORNIA, NOVEMBER 2022; PALM BEACH, FLORIDA, MARCH 2023; CANNES, FRANCE, MAY 2023; AND VENICE, ITALY, IN SEPTEMBER 2023. CELEBRITY SUPPORT AMFAR'S PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATION'S MISSION. SUPPORT OF AMFAR FROM PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFAR'S FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD.CELEBRITY SUPPORTERS INCLUDED ANGELA BASSETT, KATE BECKINSALE, ORLANDO BLOOM, MATTEO BOCELLI, KELLY CLARKSON, ROBERT DE NIRO, LEONARDO DICAPRIO, AVA DUVERNAY, JAY ELLIS, LUKE EVANS, EMILY HAMPSHIRE, ED HARRIS, ETHAN HAWKE, TOMMY HILFIGER, CHEYENNE JACKSON, SCARLETT JOHANSSON, EARVIN "MAGIC" JOHNSON, MILLA JOVOVICH, HEIDI KLUM, GLADYS KNIGHT, JANE KRAKOWSKI, ADAM LAMBERT, JULIAN LENNON, LEONA LEWIS, EVA LONGORIA, JANE LYNCH, TOBEY MAGUIRE, JAMES MARSDEN, CATHERINE O'HARA, KEKE PALMER, TYLER PERRY, QUEEN LATIFAH, RITA ORA, SHERYL LEE RALPH, BEBE REXHA, COCO ROCHA, MICHELLE RODRIGUEZ, CARINE ROITFELD, JEREMY SCOTT, TROYE SIVAN, ALEXANDER SKARSGRD, KENAN THOMPSON, BELLA THORNE, ELLEN VON UNWERTH, TAIKA WAITITI, JESSE WILLIAMS, REBEL WILSON, AND JEFFREY WRIGHT.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (2 entries)

ExpenseExpenseAmt	GrantGrantAmt	RevenueRevenueAmt	DescDesc
$2,276,417	$138,000	$61,777	PUBLIC POLICYENDING THE HIV EPIDEMIC IN THE U.S.THROUGHOUT THE YEAR, THE AMFAR POLICY TEAM WORKED CLOSELY WITH MEMBERS OF THE BIDEN ADMINISTRATION, THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), NATIONAL INSTITUTES OF HEALTH (NIH), AND THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC AND DISCUSS POLICY INITIATIVES. AMFAR FOCUSED MUCH OF ITS EFFORTS ON KEEPING DOMESTIC AND INTERNATIONAL HIV FUNDING ON TRACK AND CONTINUING ITS DATA-DRIVEN ADVOCACY OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY, WHILE ENGAGING IN EFFORTS TO EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, PROMOTING HARM REDUCTION POLICIES AIMED AT REDUCING THE TRANSMISSION OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECTING THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. SAFEGUARDING HIV PROGRAMSIN EARLY 2023, THE GOVERNOR OF TENNESSEE ANNOUNCED THE STATE'S REJECTION OF FEDERAL FUNDS FOR HIV PREVENTION AND UNVEILED A REVISED TENNESSEE DEPARTMENT OF HEALTH PREVENTION STRATEGY SHIFTING FOCUS AWAY FROM THE MOST VULNERABLE POPULATIONS. IN RESPONSE, AMFAR PRODUCED AND DISTRIBUTED TO CONGRESSIONAL OFFICES AN INFOGRAPHIC ILLUSTRATING HOW THE NEW FOCUS WOULD MISS THOSE MOST AT RISK OF INFECTION, AND MET WITH STAKEHOLDERS FROM TENNESSEE AND THE CDC DIVISION OF HIV PREVENTION. TO INFORM THE PUBLIC ABOUT THIS ISSUE, AMFAR WAS INTERVIEWED BY THE NEW YORK TIMES, WASHINGTON POST, PBS, NPR, AND NBC NEWS.IN ADDITION, THE POLICY TEAM INITIATED AN ANALYSIS OF THE NUMBER OF UNDIAGNOSED HIV INFECTIONS IN THE U.S., AND THE HUMAN AND ECONOMIC COSTS IF OTHER STATES WERE TO FOLLOW IN THE FOOTSTEPS OF TENNESSEE AND REFUSE FEDERAL HIV PREVENTION FUNDING. PARTNERING WITH FUNDERS CONCERNED ABOUT AIDS, AMFAR ALSO PRODUCED A TIMELY INFOGRAPHIC, ENDING HIV: ZERO OUT THE EPIDEMIC NOT THE BUDGET, TO DEMONSTRATE THE POTENTIAL IMPACT OF PROPOSED CUTS TO FEDERAL HIV FUNDING IN A FY24 APPROPRIATIONS BILL INTRODUCED TO THE HOUSE OF REPRESENTATIVES. LEARNING FROM MPOXTHE PUBLIC POLICY OFFICE ADVISED THE WHITE HOUSE GLOBAL MPOX COORDINATOR ON ONGOING AND FUTURE RESPONSES, AND CO-SPONSORED A MEETING WITH GEORGETOWN LAW SCHOOL TO UNDERTAKE A POSTMORTEM OF THE DOMESTIC RESPONSE TO THE EPIDEMIC. IN MAY 2023, THE POLICY TEAM PARTNERED WITH THE O'NEILL INSTITUTE AT GEORGETOWN LAW TO CO-AUTHOR COMMUNITY PARTNERSHIPS MAKE PUBLIC HEALTH MORE EFFECTIVE: LEARNING FROM THE 2022 MPOX OUTBREAK RESPONSE, AS A FOLLOW-UP TO A SERIES OF ISSUE BRIEFS ON THE EPIDEMIC. IN JULY, AMFAR AND COLUMBIA UNIVERSITY'S NYC PANDEMIC RESPONSE INSTITUTE CONVENED MORE THAN 60 STAKEHOLDERS FOR THE NATIONAL CONFERENCE TO ADVANCE EQUITY IN MPOX DIAGNOSTICS TO DETERMINE AND PRIORITIZE POLICY ACTIONS AND STRATEGIES TO IMPROVE DIAGNOSTICS DEVELOPMENT. PARTICIPANTS SUMMARIZED THEIR FINDINGS IN A PUBLISHED REPORT. AMFAR ALSO FUNDED MPOX-FOCUSED STUDIES AT HARVARD AND COLUMBIA.ENSURING GLOBAL HEALTH ACCESSAMFAR MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES, AND POLICY STAFF PARTICIPATE IN PEPFAR COUNTRY OPERATIONAL PLAN MEETINGS, THE GLOBAL FUND PARTNERSHIP FORUM, AND THE UN HIGH-LEVEL MEETINGS ON HIV/AIDS. AMFAR ENGAGES IN ADVOCACY WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES TO SECURE STRONG GLOBAL HIV BUDGETS AND CLOSELY TRACK AND RESPOND TO NEW GLOBAL HEALTH POLICIES. ADDITIONALLY, AMFAR PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN FOUR COUNTRIES. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY INITIATIVES. AMFAR LED ONGOING COMMUNITY-DRIVEN CAPACITY BUILDING EFFORTS WITH ZIMBABWE, UGANDA, AND MALAWI. IN THE U.S., THE TEAM ALSO MET WITH OFFICE OF GLOBAL AIDS COORDINATOR STAFF ON BEST PRACTICES ON COMMUNITY-LED MONITORING FUNDING AND PROJECT STRUCTURES. PRESERVING PEPFARAPPROACHING THE 20TH ANNIVERSARY OF PEPFAR AND TO MARK THE DAY THE PROGRAM'S LEGISLATION WAS PROPOSED IN THE U.S. HOUSE OF REPRESENTATIVES IN 2003, AMFAR'S PUBLIC POLICY TEAM MET WITH AMBASSADOR NKENGASONG TO DISCUSS HIS VISION, THE FUTURE OF THE PROGRAM, AND AMFAR'S CONTINUED PARTNERSHIP. ALTHOUGH THE UPDATED PEPFAR STRATEGY SHOWED GREAT POTENTIAL FOR CONTINUING THE PROGRAM'S STELLAR RECORD OF ACCOMPLISHMENT, PROPOSED CHANGES UNDER REVIEW ON CAPITOL HILL THAT COULD DERAIL ITS PROGRESS PROMPTED AMFAR TO AUTHOR A "STRUCTURED FOR SUCCESS" SERIES OF REPORTS.DISTRIBUTED TO KEY OFFICES ON CAPITOL HILL IN EARLY 2023, THE THREE REPORTS OUTLINE WHAT HAS MADE PEPFAR WORK SO WELL THUS FAR AND, FOR THE GOOD OF GLOBAL PUBLIC HEALTH, WHY ITS ANCHOR POINTS SHOULDN'T BE DISRUPTED. POLITICAL WILL, POWER, AND PROCESS IN THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) UNDERSCORES THE REASONS FOR PEPFAR'S SUSTAINABILITY; CENTRALIZED COORDINATION AUTHORITY UNDER PEPFAR VS. INTERNATIONAL PANDEMIC PREPAREDNESS ARGUES THAT PEPFAR'S MISSION MAY BE UNDERCUT BY AN ACT INTRODUCED IN CONGRESS THAT PROPOSES TO TRANSFER THE DECISION-MAKING POWER TO A NEW AMBASSADOR-AT-LARGE FOR GLOBAL HEALTH SECURITY AND DIPLOMACY; AND LEGISLATIVE PURPOSE, TARGETS, AND FOCUS UNDER PEPFAR VS. INTERNATIONAL PANDEMIC PREPAREDNESS MAPS OUT THE CONCRETE AIMS THAT HAVE BEEN DEFINED BY PEPFAR LEADERSHIP AND CONTRASTS THEM WITH THE PROPOSED CHANGES IN DECISION-MAKING AND THEIR POTENTIAL NEGATIVE EFFECTS.AS IT BECAME CLEAR THAT PEPFAR MIGHT NOT BE REAUTHORIZED IN 2023, AMFAR'S PUBLIC POLICY STAFF HELD HIGH-LEVEL MEETINGS ON CAPITOL HILL AND ESTABLISHED A SMALL WORKING GROUP WITH HIV COALITION PARTNERS TO STRENGTHEN ADVOCACY WITH POLICYMAKERS.EMPOWERMENT THROUGH DATAAMFAR IS AT THE FOREFRONT OF DATA COLLECTION FOR ADVOCACY PURPOSES, FORTIFYING PUBLIC HEALTH RESPONSES WITH ACCURATE INFORMATION. IN FY2023, FOR EXAMPLE, AMFAR ADVISED BOTH THE CDC AND JOHNS HOPKINS UNIVERSITY ON MODERNIZING COVID-19 DATA COLLECTION. AND, DURING A WEEK OF IN-PERSON CAPACITY BUILDING IN LESOTHO, THE PUBLIC POLICY OFFICE LED DATA TRAININGS TO REPRESENT THE NEEDS OF ADOLESCENT GIRLS AND YOUNG WOMEN IN ADVOCACY EFFORTS.IN ADDITION, AMFAR MAINTAINS A SUITE OF FREE INTERACTIVE DATABASES THAT ARE INVALUABLE RESOURCES FOR INDIVIDUALS AND ORGANIZATIONS WORKING TO SECURE AND MONITOR HIV-RELATED FUNDING AND TAILOR PROGRAMS TO MEET THE NEEDS OF CLIENTS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS DATA AND PREPARE ADVOCACY INITIATIVES. PEPFAR MONITORING, EVALUATION, AND REPORTING (MER.AMFAR.ORG): THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. PEPFAR COUNTRY/REGIONAL OPERATIONAL PLANS (COPSDATA.AMFAR.ORG): A COMPLEMENT TO THE MER DATABASE, COPS HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY, AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS. KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG): LAUNCHED IN 2021, THE DATA PROJECT BRINGS TOGETHER AVAILABLE DATA ON KEY POPULATIONS DEMOGRAPHICS, EPIDEMIOLOGY, FUNDING, AND PROGRAMMING FROM UNAIDS, PEPFAR, AND THE GLOBAL FUND. THIS RESOURCE INCLUDES COUNTRY FACTSHEETS SHOWING HOW FUNDING HAS EVOLVED OVER TIME, AND, WHERE POSSIBLE, IDENTIFIES WHO IS RESPONSIBLE FOR IMPLEMENTING KP PROGRAMMING IN THE PEPFAR PROGRAM. ENDING THE HIV EPIDEMIC IN THE U.S. (EHE.AMFAR.ORG): IN 2019, PRESIDENT TRUMP ANNOUNCED A PLAN TO END HIV TRANSMISSIONS IN THE U.S. BY 2030. THE ENDING THE HIV EPIDEMIC (EHE) INITIATIVE AIMS TO REDUCE HIV INFECTIONS BY 75% IN FIVE YEARS, AND BY 90% IN TEN YEARS. TO HELP POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS UNDERSTAND THE OPPORTUNITIES AND CHALLENGES ACROSS EHE JURISDICTIONS, AMFAR MAINTAINS A FREE INTERACTIVE DATABASE THAT INCLUDES DEMOGRAPHIC, POLICY, AND SERVICE PROVIDER INFORMATION, AND EPIDEMIOLOGICAL INDICATORS.OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG): AMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES.SHARING KNOWLEDGE, AMPLIFYING EXPERTISEIN DECEMBER 2022, AMFAR AND GLOBAL ACTION FOR TRANS EQUALITY (GATE) RELEASED A NEW REPORT, INCREASING TRANS INCLUSION IN HIV/AIDS NATIONAL STRATEGIC PLANNING: LEARNINGS FROM COMMUNITY ADVOCACY IN FIVE COUNTRIES. BASED ON A YEARLONG PROJECT, THE REPORT AIMED TO INCREASE TRANS INCLUSION IN NATIONAL STRATEGIC PLANS FOR HIV/AIDS BY
			BY BUILDING THE CAPACITY OF FIVE TRANS-LED COMMUNITY ORGANIZATIONS TO ENGAGE IN NSP-FOCUSED ADVOCACY AND SHAPE TRANS-SPECIFIC PROGRAMMING.IN 2023, AMFAR STAFF PUBLISHED THREE ARTICLES IN ACADEMIC JOURNALS WITH FAR-REACHING POLICY IMPLICATIONS. IN THE LANCET HIV IN MARCH, GREG MILLETT, MPH, AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY, CO-AUTHORED "ASSOCIATIONS BETWEEN PUNITIVE POLICIES AND LEGAL BARRIERS TO CONSENSUAL SAME-SEXUAL ACTS AMONG GAY MEN IN SUB-SAHARAN AFRICA," POOLING DATA FROM TEN COUNTRY-SPECIFIC, CROSS-SECTIONAL STUDIES CONDUCTED IN 25 SITES ACROSS THE REGION.THE JOURNAL OF THE INTERNATIONAL AIDS SOCIETY PUBLISHED A "VIEWPOINT" WARNING THAT THE U.S. GOVERNMENT'S PROPOSED RECONFIGURATION OF GLOBAL HEALTH FUNCTIONS WOULD NEGATIVELY IMPACT PEPFAR. WRITTEN BY GREG MILLETT, INDEPENDENT SCHOLAR EMILY BASS, AND BRIAN HONERMANN, AMFAR DEPUTY DIRECTOR OF PUBLIC POLICY, THE COMMENTARY OUTLINED THE WAYS IN WHICH TAMPERING WITH PEPFAR WOULD NOT ONLY WASTE TIME AND MONEY, BUT ALSO UPEND PROGRESS ON AIDS AND HAMPER OUR RESPONSE TO OTHER PANDEMICS.IN THE DECEMBER ISSUE OF THE JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, GREG MILLETT CO-AUTHORED "THERE IS NO ENDING AIDS BY 2030 WITHOUT IMPROVING HUMAN RIGHTS," WHICH ILLUMINATED THE WAYS IN WHICH SUBOPTIMAL HUMAN RIGHTS CAN LEAD TO NEGATIVE HIV-RELATED HEALTH OUTCOMES.AMFAR NUMEROUS PRESENTATIONS AND PANELS AT MEETINGS AND CONFERENCES THROUGHOUT THE YEAR, AMFAR PARTICIPATED IN THE 2023 INTERNATIONAL AIDS CONFERENCE ON HIV SCIENCE (IAS 2023) IN BRISBANE, AUSTRALIA. MEMBERS OF THE PUBLIC POLICY TEAM AUTHORED FIVE ABSTRACTS, COVERING TOPICS SUCH AS PEPFAR'S RECENCY SURVEILLANCE STRATEGY, QUALITY OF CARE FOR KEY POPULATIONS, AND COMMUNITY-LED MONITORING IN SOUTH AFRICA, AMONG OTHERS.

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$2,276,417	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$138,000	TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue	$61,777	TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses	$24,729,591	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	Yes (1)	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (1)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	Yes (1)	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	Yes (1)	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (1)	ProfessionalFundraisingInd
Fundraising Activities	Yes (1)	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	128	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Employee	79	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (1)	ForeignFinancialAccountInd
Foreign Country	TH	ForeignCountryCd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (1)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (1)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	14	GoverningBodyVotingMembersCnt
Independent Voting Member	14	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	Yes (1)	LocalChaptersInd
Policies Reference Chapters	Yes (1)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Other Website	Yes (X)	OtherWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	BRADLEY JENSEN	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	2128061600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (29 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
T RYAN GREENWALT
CO-CHAIR	1.00	Yes (X)	Yes (X)	$0	$0	$0
KEVIN MCCLATCHY
CO-CHAIR	1.00	Yes (X)	Yes (X)	$0	$0	$0
JAY ELLIS
SECRETARY	1.00	Yes (X)	Yes (X)	$0	$0	$0
DONALD DYE
TREASURER	1.00	Yes (X)		$0	$0	$0
GLEN ISAACSON
TRUSTEE	1.00	Yes (X)		$0	$0	$0
MICHAEL LORBER
TRUSTEE	1.00	Yes (X)		$0	$0	$0
LARRY MILSTEIN
TRUSTEE	1.00	Yes (X)		$0	$0	$0
CINDY RACHOFSKY
TRUSTEE	1.00	Yes (X)		$0	$0	$0
VINCENT A ROBERTI
TRUSTEE	1.00	Yes (X)		$0	$0	$0
MERV SILVERMAN
TRUSTEE	1.00	Yes (X)		$0	$0	$0
JEFFREY SCHOENFELD
TRUSTEE	1.00	Yes (X)		$0	$0	$0
MARIO STEVENSON
TRUSTEE	1.00	Yes (X)		$0	$0	$0
ROBERT L TRAYNHAM II
TRUSTEE	1.00	Yes (X)		$0	$0	$0
PHILL WILSON
TRUSTEE	1.00	Yes (X)		$0	$0	$0
AMY ANDELSON
TRUSTEE, THRU SEPT 2023	1.00	Yes (X)		$0	$0	$0
KEVIN FROST
CHIEF EXECUTIVE OFFICER	40.00		Yes (X)	$495,839	$0	$115,008
BRADLEY JENSEN
ASSISTANT TREASURER/CFO	40.00		Yes (X)	$269,474	$0	$75,520
SEBASTIAN GHEITH
ASSOCIATE COUNSEL, ASST SECRETARY	40.00		Yes (X)	$172,644	$0	$85,778
ROWENA JOHNSTON
ASST SEC, VP, RESEARCH	40.00		Yes (X)	$212,987	$0	$38,751
EDWARD DONNELLY
ASSISTANT TREASURER, CONTROLLER	40.00		Yes (X)	$172,151	$0	$32,068
KYLE CLIFFORD
VICE PRESIDENT OF DEVELOPMENT	40.00			$244,113	$0	$74,185	Yes (X)
ANNMARIE SHANNAHAN VP
PUBLIC INFORMATION, THRU SEPT 2022	40.00			$177,055	$0	$54,181	Yes (X)
ANNETTE SOHN
VICE PRESIDENT, TREAT ASIA PROGRAM	40.00			$257,278	$0	$27,200	Yes (X)
GREGORIO MILLET
VICE PRESIDENT, PUBLIC POLICY	40.00			$186,375	$0	$70,010	Yes (X)
ANTHONY ANCONA
VICE PRESIDENT OF HUMAN RESOURCES	40.00			$192,343	$0	$70,491		Yes (X)
ANDREW MCINNES
DIRECTOR, PUBLICATIONS	40.00			$176,315	$0	$69,136		Yes (X)
JOSEPH FERRERA
DIRECTOR, PHILANTHROPY	40.00			$170,060	$0	$85,531		Yes (X)
CASSANDRA DAWES MANAGER OF
SPECIAL EVENTS THRU MAY 2022	40.00			$179,646	$0	$15,045		Yes (X)
SUSAN DOSTER
CHIEF TECHNOLOGY OFFICER	40.00			$156,800	$0	$35,159		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,063,080	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$848,063	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	23	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SANKY COMMUNICATIONS INC
360 W 31ST ST FL 6	NEW YORK	NY	10001	DIRECT MAIL/RESPONSE CONSULTANTS	$512,455
TODD EVENT DESIGN
1174 QUAKER STREET	DALLAS	TX	75207	EVENT PRODUCTION	$384,911
VAN WYCK & VAN WYCK INC
122 WEST 27TH ST 12TH FLOOR	NEW YORK	NY	10001	EVENT MANAGEMENT	$331,195
AAB PRODUCTIONS INC
64 ALLEN ROAD 5TH FLOOR	NEW YORK	NY	10002	EVENT PRODUCTION	$290,000
TECHNICAL ARTS GROUP LLC
1 COUNTY ROAD BLDG B12	SECAUCUS	NY	07094	EVENT PRODUCTION	$282,127

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	16	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$82,024	FederatedCampaignsAmt
Fundraising	$27,515,022	FundraisingAmt
Government Grants	$9,975,231	GovernmentGrantsAmt
All Other Contributions	$4,643,857	AllOtherContributionsAmt
Noncash Contributions	$83,578	NoncashContributionsAmt
Total Contributions	$42,216,134	TotalContributionsAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,239,822	TotalRevenueColumnAmt
Exclusion	$1,239,822	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$62,091	TotalRevenueColumnAmt
Exclusion	$62,091	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$6,134,783	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$6,468,186	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	-$333,403	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$333,403	TotalRevenueColumnAmt
Exclusion	-$333,403	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$1,203,966	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$27,515,022	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$15,370,385	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$14,166,419	TotalRevenueColumnAmt
Exclusion	-$14,166,419	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$2,590	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$2,590	TotalRevenueColumnAmt
Exclusion	$2,590	ExclusionAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$62,802	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$1,025	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$61,777	TotalRevenueColumnAmt
Related Or Exempt Func Income	$61,777	RelatedOrExemptFuncIncomeAmt

Other Revenue Misc OtherRevenueMiscGrp

Field	Value	IRS element (for citing)
Desc	MISCELLANEOUS INCOME	Desc
Business	900099	BusinessCd
Total Revenue Column	$115	TotalRevenueColumnAmt
Exclusion	$115	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$115	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$29,082,707	TotalRevenueColumnAmt
Related Or Exempt Func Income	$61,777	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$13,195,204	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$3,276,032	TotalAmt
Program Services	$3,276,032	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$2,471,120	TotalAmt
Program Services	$2,471,120	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,957,936	TotalAmt
Program Services	$2,097,455	ProgramServicesAmt
Management And General	$372,561	ManagementAndGeneralAmt
Fundraising	$487,920	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$5,789,423	TotalAmt
Program Services	$3,712,007	ProgramServicesAmt
Management And General	$582,939	ManagementAndGeneralAmt
Fundraising	$1,494,477	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$367,395	TotalAmt
Program Services	$245,671	ProgramServicesAmt
Management And General	$38,452	ManagementAndGeneralAmt
Fundraising	$83,272	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,897,976	TotalAmt
Program Services	$1,242,075	ProgramServicesAmt
Management And General	$270,763	ManagementAndGeneralAmt
Fundraising	$385,138	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$544,380	TotalAmt
Program Services	$341,960	ProgramServicesAmt
Management And General	$61,746	ManagementAndGeneralAmt
Fundraising	$140,674	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$49,583	TotalAmt
Program Services	$43,350	ProgramServicesAmt
Management And General	$5,363	ManagementAndGeneralAmt
Fundraising	$870	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$177,754	TotalAmt
Management And General	$177,754	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$110,000	TotalAmt
Program Services	$110,000	ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$525,768	TotalAmt
Fundraising	$525,768	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$210,971	TotalAmt
Management And General	$210,971	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$1,054,573	TotalAmt
Program Services	$428,016	ProgramServicesAmt
Management And General	$140,547	ManagementAndGeneralAmt
Fundraising	$486,010	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$278,105	TotalAmt
Program Services	$214,530	ProgramServicesAmt
Management And General	$4,177	ManagementAndGeneralAmt
Fundraising	$59,398	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$130,660	TotalAmt
Program Services	$56,055	ProgramServicesAmt
Management And General	$11,417	ManagementAndGeneralAmt
Fundraising	$63,188	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$221,333	TotalAmt
Program Services	$146,085	ProgramServicesAmt
Management And General	$31,681	ManagementAndGeneralAmt
Fundraising	$43,567	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$1,618,265	TotalAmt
Program Services	$1,053,438	ProgramServicesAmt
Management And General	$238,490	ManagementAndGeneralAmt
Fundraising	$326,337	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,512,791	TotalAmt
Program Services	$551,862	ProgramServicesAmt
Management And General	$3,188	ManagementAndGeneralAmt
Fundraising	$957,741	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$489,540	TotalAmt
Program Services	$459,128	ProgramServicesAmt
Management And General	$7,365	ManagementAndGeneralAmt
Fundraising	$23,047	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$62,385	TotalAmt
Program Services	$40,615	ProgramServicesAmt
Management And General	$9,195	ManagementAndGeneralAmt
Fundraising	$12,575	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$426,820	TotalAmt
Program Services	$277,875	ProgramServicesAmt
Management And General	$62,909	ManagementAndGeneralAmt
Fundraising	$86,036	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$347,834	TotalAmt
Program Services	$226,452	ProgramServicesAmt
Management And General	$51,267	ManagementAndGeneralAmt
Fundraising	$70,115	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PROGRAM MATERIALS	$5,931,960	$5,931,960
PROGRAM TECHNICAL SUPPO	$761,638	$761,638
PRINTING	$585,615	$86,171	$380	$499,064
SUBSCRIPTION & DUES	$577,776	$388,838	$76,143	$112,795

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$1,562,613	TotalAmt
Program Services	$567,258	ProgramServicesAmt
Management And General	$331,101	ManagementAndGeneralAmt
Fundraising	$664,254	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$33,940,246	TotalAmt
Program Services	$24,729,591	ProgramServicesAmt
Management And General	$2,688,409	ManagementAndGeneralAmt
Fundraising	$6,522,246	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$4,392,774	BOYAmt
EOY	$791,311	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$868,721	BOYAmt
EOY	$635,034	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$92,474	BOYAmt
EOY	$81,603	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$9,810,449	BOYAmt
EOY	$7,282,525	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$544,666	BOYAmt
EOY	$95,730	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$2,405,901	BOYAmt
EOY	$1,792,963	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$8,374,765	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$6,096,008	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$2,435,956	BOYAmt
EOY	$2,278,757	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$34,244,287	BOYAmt
EOY	$33,561,440	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$390,809	BOYAmt
EOY	$4,199,800	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$55,186,037	BOYAmt
EOY	$50,719,163	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$3,431,342	BOYAmt
EOY	$6,278,878	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$743,456	BOYAmt
EOY	$669,464	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$13,553,638	BOYAmt
EOY	$5,040,944	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$850,000	BOYAmt
EOY	$1,311,267	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$1,513,249	BOYAmt
EOY	$5,048,985	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$20,091,685	BOYAmt
EOY	$18,349,538	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$32,671,728	BOYAmt
EOY	$29,879,962	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$2,422,624	BOYAmt
EOY	$2,489,663	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$35,094,352	BOYAmt
EOY	$32,369,625	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$55,186,037	BOYAmt
EOY	$50,719,163	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	-$4,857,539	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$2,358,975	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	-$226,163	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$40,275,703	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$21,625,761	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$28,156,638	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$43,281,833	CurrentTaxYearMinus1YearAmt
Current Tax Year	$42,216,134	CurrentTaxYearAmt
Total	$175,556,069	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$40,275,703	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$21,625,761	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$28,156,638	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$43,281,833	CurrentTaxYearMinus1YearAmt
Current Tax Year	$42,216,134	CurrentTaxYearAmt
Total	$175,556,069	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$341,368	SubstantialContributorsTotAmt
Public Support Total170	$175,214,701	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,538,331	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,252,653	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,025,000	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,328,141	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,301,913	CurrentTaxYearAmt
Total	$6,446,038	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$3,296	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$3,067	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$7,858	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$18,851	CurrentTaxYearMinus1YearAmt
Current Tax Year	$115	CurrentTaxYearAmt
Total	$33,187	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$182,035,294	TotalSupportAmt
Gross Receipts Rltd Activities	$62,802	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.96250	PublicSupportCY170Pct
Public Support PY170	0.92960	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:	FormAndLineReferenceDesc
Explanation	MISCELLANEOUS - 2018 AMOUNT: $ 1,267. 2019 AMOUNT: $ 165. 2020 AMOUNT: $ 6,555. 2022 AMOUNT: $ 115. LIST RENTALS - 2018 AMOUNT: $ 170. 2019 AMOUNT: $ 2,201. 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. STORE SALES - 2018 AMOUNT: $ 1,859. 2019 AMOUNT: $ 701. 2020 AMOUNT: $ 1,303. IRS TAX REFUND - 2021 AMOUNT: $ 18,851.	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	0	VolunteersInd
Paid Staff Or Management	Yes (1)	PaidStaffOrManagementInd
Media Advertisements	0	MediaAdvertisementsInd
Mailings Members	0	MailingsMembersInd
Publications Or Broadcast	0	PublicationsOrBroadcastInd
Grants Other Organizations	Yes (1)	GrantsOtherOrganizationsInd
Grants Other Organizations	$21,824	GrantsOtherOrganizationsAmt
Direct Contact Legislators	0	DirectContactLegislatorsInd
Rallies Demonstrations	0	RalliesDemonstrationsInd
Other Activities	Yes (1)	OtherActivitiesInd
Other Activities	$272,467	OtherActivitiesAmt
Total Lobbying Expenditures	$294,291	TotalLobbyingExpendituresAmt
Not Described Section501c3	0	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART II-B, LINE 1:	FormAndLineReferenceDesc
Explanation	THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. THE FOUNDATION ENGAGED AN INDEPENDENT CONSULTANT TO ENGAGE IN LOBBYING ACTIVITIES ON ITS BEHALF. FEES PAID TO THIS CONSULTANT TOTALED $110,000 IN THE FISCAL YEAR ENDING SEPTEMBER 30, 2023.	ExplanationTxt

Schedule D IRS990ScheduleD

Held Works Art HeldWorksArtGrp

Field	Value	IRS element (for citing)
Assets Included	$90,326	AssetsIncludedAmt

Collection Used Other Purposes CollectionUsedOtherPurposesGrp

Field	Value	IRS element (for citing)
Collection Used Other Purposes	Yes (X)	CollectionUsedOtherPurposesInd
Other Purposes	DONATED ITEMS, INVENTORY ETC.	OtherPurposesDesc

Field	Value	IRS element (for citing)
Solicited Assets Sale	Yes (1)	SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$702,275	BeginningYearBalanceAmt
Contributions	$6,450	ContributionsAmt
Investment Earnings Or Losses	$35,589	InvestmentEarningsOrLossesAmt
End Year Balance	$744,314	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$785,615	BeginningYearBalanceAmt
Contributions	$4,700	ContributionsAmt
Investment Earnings Or Losses	-$88,040	InvestmentEarningsOrLossesAmt
End Year Balance	$702,275	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$731,736	BeginningYearBalanceAmt
Contributions	$5,380	ContributionsAmt
Investment Earnings Or Losses	$48,499	InvestmentEarningsOrLossesAmt
End Year Balance	$785,615	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$701,368	BeginningYearBalanceAmt
Contributions	$7,933	ContributionsAmt
Investment Earnings Or Losses	$22,435	InvestmentEarningsOrLossesAmt
End Year Balance	$731,736	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$684,111	BeginningYearBalanceAmt
Contributions	$6,750	ContributionsAmt
Investment Earnings Or Losses	$10,507	InvestmentEarningsOrLossesAmt
End Year Balance	$701,368	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Prmnnt Endowment Balance EOY	0.54250	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.45750	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,636,465	OtherCostOrOtherBasisAmt
Depreciation	$2,024,203	DepreciationAmt
Book Value	$612,262	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,060,191	OtherCostOrOtherBasisAmt
Depreciation	$1,052,226	DepreciationAmt
Book Value	$7,965	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$4,678,109	OtherCostOrOtherBasisAmt
Depreciation	$3,019,579	DepreciationAmt
Book Value	$1,658,530	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$2,278,757	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp (4 entries)

DescDesc	Book ValueBookValueAmt
SECURITY DEPOSITS	$50,840
RIGHT OF USE ASSETS	$3,715,594
DEBT SERVICE RESERVE	$409,026
EMPLOYEE ADVANCES	$24,340

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$4,199,800	TotalBookValueOtherAssetsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
SEC. 457 RETIREMENT LIABILITY	$409,026
OPERATING LEASES	$4,639,959

Field	Value	IRS element (for citing)
Total Liability	$5,048,985	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$31,246,536	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$2,358,975	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$14,800	DonatedServicesAndUseFcltsAmt
Other Revenue	$1,025	OtherRevenueAmt
Revenue Not Reported	$2,374,800	RevenueNotReportedAmt
Revenue Subtotal	$28,871,736	RevenueSubtotalAmt
Investment Expenses Not Incld	$210,971	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$210,971	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$29,082,707	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$33,971,263	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$14,800	DonatedServicesUseFcltsAmt
Other Expenses Included	$556,447	OtherExpensesIncludedAmt
Expenses Not Reported	$571,247	ExpensesNotReportedAmt
Expenses Subtotal	$33,400,016	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$210,971	InvestmentExpensesNotIncld2Amt
Other Expenses Not Included	$329,259	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$540,230	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$33,940,246	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (6 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART III, LINE 4:	AMFAR SOLICITS ARTWORK FOR OUR EVENT AUCTIONS ARTWORK MAY BE DONATED OUTRIGHT, ON CONSIGNMENT OR SOMETIMES AMFAR PURCHASES THE PIECE IF IT CAN BE AUCTIONED WITH A LARGE ENOUGH RETURN. SOME ARE OUTRIGHT DONATIONS TO BE AUCTIONED AND SOME ARE PROVIDED ON CONSIGNMENT FOR THE AUCTION.
PART V, LINE 4:	AMFAR'S ENDOWMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS.
PART X, LINE 2:	AMFAR RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT AMFAR HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. AMFAR IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIODS PRIOR TO 2020.
PART XI, LINE 2D - OTHER ADJUSTMENTS:	COST OF GOODS SOLD REPORTED ON PART VIII, LINE 10B 1,025.
PART XII, LINE 2D - OTHER ADJUSTMENTS:	COST OF GOODS SOLD REPORTED ON PART VIII, LINE 10B 1,025. WRITE OFF OF UNCOLLECTIBLE PLEDGES 555,422.
PART XII, LINE 4B - OTHER ADJUSTMENTS:	RECLASS OF OVERACCRUAL OF GRANT EXPENSES 329,259.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	0	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (5 entries)

RegionRegionTxt	OfficesOfficesCnt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND & GREENLAND)	0	0	FUNDRAISING SERVICES	THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING	$9,936,068
EUROPE (INCLUDING ICELAND & GREENLAND)	0	0	GRANTMAKING		$727,288
SOUTH ASIA	0	0	GRANTMAKING		$157,205
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		$1,586,627
EAST ASIA AND THE PACIFIC	1	15	PROGRAM SERVICES	THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING	$1,908,561

Field	Value	IRS element (for citing)
Subtotal Offices	1	SubtotalOfficesCnt
Subtotal Employees	15	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	1	TotalOfficeCnt
Total Employee	15	TotalEmployeeCnt
Subtotal Spent	$14,315,749	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$14,315,749	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (43 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
EAST ASIA AND THE PACIFIC	TREAT ASIA	$492,175	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	RESEARCH	$139,817	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	RESEARCH	$106,088	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$85,519	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$81,064	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$79,138	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$74,599	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$55,263	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$45,558	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$33,446	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$32,341	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$28,277	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$28,175	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,000	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,000	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,000	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$19,999	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$19,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$16,000	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$13,974	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$13,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$13,000	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$12,276	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$10,221	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$9,000	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$8,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,275	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,125	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,975	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,675	WIRE TRANSFER	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,000	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	RESEARCH	$609,788	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	RESEARCH	$80,000	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	RESEARCH	$37,500	WIRE TRANSFER	$0
SOUTH ASIA	TREAT ASIA	$108,974	WIRE TRANSFER	$0
SOUTH ASIA	TREAT ASIA	$15,735	WIRE TRANSFER	$0
SOUTH ASIA	TREAT ASIA	$32,496	WIRE TRANSFER	$0

Field	Value	IRS element (for citing)
Total501c3 Org	43	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART I, LINE 2:

FOREIGN ACTIVITIES INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE, PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH STEPS REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORT IN ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES - PART I, LINE 3, COLUMN D: THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 43 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S CHARITIES.

PART III ACCOUNTING METHOD:

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Solicitation Of Govt Grants	Yes (X)	SolicitationOfGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (1)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (2 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
AAB PRODUCTIONS
387 GRAND STREET SUITE K705	NEW YORK	NY	10002	SPECIAL EVENT PRODUCTION	0	$19,027,141	$330,000	$18,697,141
SANKY COMMUNICATIONS INC
360 W 31ST STREET FLOOR 6	NEW YORK	NY	10001	DIRECT MAIL DIRECT RESPONSE CONSULTING	0	$1,221,208	$360,768	$860,440

Field	Value	IRS element (for citing)
Total Gross Receipts	$20,248,349	TotalGrossReceiptsAmt
Total Retained By Contractors	$690,768	TotalRetainedByContractorsAmt
Total Net To Organization	$19,557,581	TotalNetToOrganizationAmt
Licensed States	AL	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	AZ	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DE	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	ID	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	IN	LicensedStatesCd
Licensed States	IA	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MT	LicensedStatesCd
Licensed States	NE	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	SD	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd
Licensed States	WY	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	CANNES GALA	Event1Nm
Gross Receipts Event1	$13,449,760	GrossReceiptsEvent1Amt
Charitable Contri Event1	$13,030,760	CharitableContriEvent1Amt
Gross Revenue Event1	$419,000	GrossRevenueEvent1Amt
Rent Facility Costs Event1	$1,080,643	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$380,824	FoodAndBeverageEvent1Amt
Entertainment Event1	$1,581,363	EntertainmentEvent1Amt
Other Direct Expenses Event1	$5,222,768	OtherDirectExpensesEvent1Amt
Event2	DALLAS TWO BY TWO	Event2Nm
Gross Receipts Event2	$5,437,537	GrossReceiptsEvent2Amt
Charitable Contri Event2	$5,194,595	CharitableContriEvent2Amt
Gross Revenue Event2	$242,942	GrossRevenueEvent2Amt
Rent Facility Costs Event2	$223,810	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$299,185	FoodAndBeverageEvent2Amt
Entertainment Event2	$159,551	EntertainmentEvent2Amt
Other Direct Expenses Event2	$1,075,839	OtherDirectExpensesEvent2Amt
Other Events Total	3	OtherEventsTotalCnt
Gross Receipts Other Events	$9,831,691	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$9,289,667	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$542,024	GrossRevenueOtherEventsAmt
Rent Fclty Costs Other Events	$653,131	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$501,052	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$1,319,153	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$2,873,066	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$28,718,988	GrossReceiptsTotalAmt
Charitable Contributions Tot	$27,515,022	CharitableContributionsTotAmt
Gross Revenue Total Events	$1,203,966	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$1,957,584	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$1,181,061	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$3,060,067	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$9,171,673	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$15,370,385	DirectExpenseSummaryEventsAmt
Net Income Summary	-$14,166,419	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2B, COLUMN (V):	FormAndLineReferenceDesc
Explanation	THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $525,768 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2023. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $690,768. OF THAT $690,768 ONLY $525,768 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $165,000 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN PART VII). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (19 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt	Address Line2USAddress/AddressLine2Txt
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02144	042697983	501(C)(3)	$949,169	$0	RESEARCH
CHARITIES AID FOUNDATION OF AMERICA
225 REINEKERS LANE SUITE 375	ALEXANDRIA	VA	22314	431634280	501(C)(3)	$837,920	$0	RESEARCH
UNIVERSITY OF CALIFORNIA LOS ANGELES
10889 WILSHIRE BOULEVARD SUITE 700	LOS ANGELES	CA	90095	956006143	501(C)(3)	$260,000	$0	RESEARCH
THE WISTAR INSTITUTE
3601 SPRUCE STREET	PHILADELPHIA	PA	19104	236434390	501(C)(3)	$243,155	$0	RESEARCH
JOHNS HOPKINS UNIVERSITY
733 N BROADWAY MRB SUITE 117	BALTIMORE	MD	21287	520595110	501(C)(3)	$151,987	$0	TREAT ASIA
UNIVERSITY OF PENNSYLVANIA
3451 WALNUT STREET 5TH FLOOR	PHILADELPHIA	PA	191046250	231352685	501(C)(3)	$147,598	$0	RESEARCH	FRANKLIN BUILDING
UNIVERSITY OF MINNESOTA
200 OAK STREET SE	MINNEAPOLIS	MN	55455	416007513	501(C)(3)	$128,465	$0	RESEARCH
COLUMBIA UNIVERSITY
630 WEST 168TH ST BOX 49	NEW YORK	NY	100323702	135598093	501(C)(3)	$102,301	$0	PUBLIC POLICY
UNIVERSITY OF MIAMI
1320 S DIXIE HIGHWAY SUITE 650	CORAL GABLES	FL	33146	590624458	501(C)(3)	$75,000	$0	RESEARCH
INDIANA UNIVERSITY
635 BARNHILL DR MS420	INDIANAPOLIS	IN	46202	356001673	501(C)(3)	$75,000	$0	RESEARCH
UNIVERSITY OF WASHINGTON
4333 BROOKLYN AVENUE NE BOX 359472	SEATTLE	WA	981959472	906001537	501(C)(3)	$74,257	$0	RESEARCH
FENWAY COMMUNITY HEALTH CENTER INC
1340 BOYLSTON STREET	BOSTON	MA	02215	042510564	501(C)(3)	$50,000	$0	RESEARCH
EMORY UNIVERSITY
1599 CLIFTON ROAD	ATLANTA	GA	303224250	580566256	501(C)(3)	$40,000	$0	PUBLIC POLICY
NATIONAL FOUNDATION FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION INC
600 PEACHTREE STREET NE SUITE 1000	ATLANTA	GA	202081120	582106707	501(C)(3)	$38,025	$0	TREAT ASIA
GLADSTONE INSTITUTE
1650 OWENS STREET	SAN FRANCISCO	CA	94158	237203666	501(C)(3)	$25,000	$0	RESEARCH
PREP4ALL INC
185 BALL STREET 105	BROOKLYN	NY	11205	853596607	501(C)(3)	$23,000	$0	PUBLIC POLICY
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
3333 CALIFORNIA STREET SUITE 315	SAN FRANCISCO	CA	94143	943067788	501(C)(3)	$20,000	$0	RESEARCH
RESEARCH FOUNDATION FOR MENTAL HYGIENE INC
150 BROADWAY SUITE 301	MENANDS	NY	12204	141410842	501(C)(3)	$19,744	$0	TREAT ASIA
FRED HUTCHINSON CANCER CENTER
1100 FAIRVIEW AVENUE N	SEATTLE	WA	98109	911935159	501(C)(3)	$10,411	$0	RESEARCH

Field	Value	IRS element (for citing)
Total501c3 Org	20	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH SUBAWARD TERMS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (1)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
KEVIN FROST
CHIEF EXECUTIVE OFFICER	$460,327	$0	$0	$0	$35,512	$0	$41,850	$0	$73,158	$0	$610,847	$0	$0	$0
BRADLEY JENSEN
ASSISTANT TREASURER/CFO	$269,474	$0	$0	$0	$0	$0	$19,010	$0	$56,510	$0	$344,994	$0	$0	$0
KYLE CLIFFORD
VICE PRESIDENT OF DEVELOPMENT	$244,113	$0	$0	$0	$0	$0	$17,675	$0	$56,510	$0	$318,298	$0	$0	$0
ANNETTE SOHN
VICE PRESIDENT, TREAT ASIA PROGRAM	$257,278	$0	$0	$0	$0	$0	$18,004	$0	$9,196	$0	$284,478	$0	$0	$0
ANTHONY ANCONA
VICE PRESIDENT OF HUMAN RESOURCES	$192,343	$0	$0	$0	$0	$0	$13,981	$0	$56,510	$0	$262,834	$0	$0	$0
SEBASTIAN GHEITH
ASSOCIATE COUNSEL, ASST SECRETARY	$172,644	$0	$0	$0	$0	$0	$12,620	$0	$73,158	$0	$258,422	$0	$0	$0
GREGORIO MILLET
VICE PRESIDENT, PUBLIC POLICY	$186,375	$0	$0	$0	$0	$0	$13,500	$0	$56,510	$0	$256,385	$0	$0	$0
JOSEPH FERRERA
DIRECTOR, PHILANTHROPY	$170,060	$0	$0	$0	$0	$0	$12,373	$0	$73,158	$0	$255,591	$0	$0	$0
ROWENA JOHNSTON
ASST SEC, VP, RESEARCH	$212,987	$0	$0	$0	$0	$0	$15,004	$0	$23,747	$0	$251,738	$0	$0	$0
ANDREW MCINNES
DIRECTOR, PUBLICATIONS	$176,315	$0	$0	$0	$0	$0	$12,626	$0	$56,510	$0	$245,451	$0	$0	$0
ANNMARIE SHANNAHAN VP
PUBLIC INFORMATION, THRU SEPT 2022	$177,055	$0	$0	$0	$0	$0	$12,711	$0	$41,470	$0	$231,236	$0	$0	$0
EDWARD DONNELLY
ASSISTANT TREASURER, CONTROLLER	$172,151	$0	$0	$0	$0	$0	$12,433	$0	$19,635	$0	$204,219	$0	$0	$0
CASSANDRA DAWES MANAGER OF
SPECIAL EVENTS THRU MAY 2022	$179,646	$0	$0	$0	$0	$0	$5,362	$0	$9,683	$0	$194,691	$0	$0	$0
SUSAN DOSTER
CHIEF TECHNOLOGY OFFICER	$156,800	$0	$0	$0	$0	$0	$11,412	$0	$23,747	$0	$191,959	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 4B	FormAndLineReferenceDesc
Explanation	CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2022, AMFAR CONTRIBUTED $35,512 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2022 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $35,512.	ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	4	ContributionCnt
Noncash Contributions Rpt F990	$83,578	NoncashContributionsRptF990Amt
Method Of Determining Revenues	AVG. SELLING PRICE	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Form8283 Received	0	Form8283ReceivedCnt
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	0	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, COLUMN (B):	FormAndLineReferenceDesc
Explanation	THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN PART I, COLUMN (B) OF SCHEDULE M.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (12 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART I, LINE 1	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: AMERICAN FOUNDATION FOR AIDS RESEARCH AMFAR AIDS RESEARCH FOUNDATION
FORM 990, PART III, LINE 1:	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: - RESEARCH TO EXPLORE SCIENTIFIC APPROACHES TO HIV PREVENTION, TREATMENT, AND POTENTIAL CURES, AND TO ENHANCE THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV/AIDS; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; - EDUCATIONAL INITIATIVES TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PUBLISH UPDATES ABOUT THE LATEST MEDICAL, SCIENTIFIC, AND PREVENTION ADVANCES FOR PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC.
FORM 990, PART III, LINE 4A	CURRENTLY USED IN THE TREATMENT OF CERTAIN CANCERS, ANTIBODY CONJUGATES BIND INTERVENTIONS TO ANTIBODIES AS A MEANS OF DELIVERING THEM TO SPECIFIC CELLS. IN THIS STUDY, DR. DE TAEYE IS TESTING SEVERAL DIFFERENT APPROACHES. THE FIRST IS A TOXIN THAT CAN BE DELIVERED TO T CELLS DISPLAYING SPECIFIC SURFACE SIGNALS. ANOTHER IS AN AGENT TO STIMULATE THE INTERNAL DEFENSES OF HIV-INFECTED CELLS, LEADING TO A CASCADE OF EVENTS THAT RESULTS IN DESTRUCTION BY THE IMMUNE SYSTEM. NAMED IN HONOR OF AMFAR'S LATE FOUNDING CHAIRMAN, THE FELLOWSHIP HAS BEEN AWARDED SINCE 2008 TO PROVIDE CRUCIAL FUNDING FOR YOUNG RESEARCHERS WHO OFTEN HAVE THE MOST INNOVATIVE AND DARING IDEAS, BUT FOR WHOM SECURING FINANCIAL SUPPORT CAN BE DIFFICULT. DR. DE TAEYE, THE 59TH MATHILDE KRIM FELLOW, IS BEING MENTORED BY DRS. ROGIER SANDERS AND MARIT VAN GILS, TWO FORMER KRIM FELLOWS, ILLUSTRATING THE EFFECTIVENESS OF THIS PROGRAM. IN ADDITION, TWO FELLOWS ALEKSANDAR ANTANASIJEVIC, PHD, OF THE ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE IN SWITZERLAND, AND JEANNETTE TENTHOREY, PHD, OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, EACH RECEIVED A PHASE II AWARD OF $50,000. CONFERENCES AND THINK TANKS IN FEBRUARY, MARK FRANKE, FORMERLY KNOWN AS THE DSSELDORF PATIENT, WAS CONFIRMED BY RESEARCHERS WORKING UNDER THE PURVIEW OF AMFAR'S ICISTEM CONSORTIUM TO BE CURED OF HIV VIA STEM CELL TRANSPLANT WITH DONOR CELLS WITH A CCR5 DELTA32 MUTATION. AT THE INTERNATIONAL AIDS CONFERENCE ON HIV SCIENCE IN JULY, DR. ASIER SEZ-CIRIN, OF THE PASTEUR INSTITUTE IN PARIS AND A MEMBER OF ICISTEM, ANNOUNCED ANOTHER NEW POSSIBLE CASE OF CURE (THE GENEVA PATIENT) USING A SIMILAR STRATEGY BUT THIS TIME USING DONOR CELLS WITHOUT THE MUTATION. RESEARCHERS ARE STILL MONITORING THE PATIENT TO DETERMINE HIS CURE STATUS. IN APRIL, AMFAR CONVENED A TWO-DAY THINK TANK WITH 13 SCIENTISTS IN WASHINGTON, D.C., TO DISCUSS THE ROLE OF ANTI-HIV ANTIBODIES IN THE OPTIMIZATION OF HIV CURE STRATEGIES, FOCUSING ON THE ROLE OF BROADLY NEUTRALIZING ANTIBODIES IN ERADICATING HIV RESERVOIRS. PARTICIPANTS INCLUDED REPRESENTATIVES FROM ACADEMIA AND THE NIH, AS WELL AS RESEARCHERS FROM DENMARK AND LONDON (VIA ZOOM). PUBLISHED RESEARCH AMFAR IS A LEADING VOICE IN THE SCIENTIFIC CONVERSATION PERTAINING TO HIV, AS EVIDENCED BY THE MANY AMFAR-FUNDED RESEARCH STUDIES PUBLISHED IN PEER-REVIEWED JOURNALS. IN FY2023, 30 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. HIGHLIGHTS INCLUDE: A STEP TOWARD ELIMINATING RESERVOIR CELLS? HIV RESERVOIRS, THE PRIMARY IMPEDIMENT TO A CURE FOR HIV, PREDOMINANTLY INVOLVE CD4 MEMORY T CELLS. BUT SOME SUBTYPES OF THOSE RESERVOIR CELLS THAT COULD BE TARGETED IN A CURE STRATEGY MAY REPRESENT MUCH GREATER OBSTACLES THAN OTHERS BECAUSE THEY ARE BOTH ENRICHED FOR LATENT HIV AND BETTER ABLE TO RESIST REACTIVATION. A COLLABORATIVE RESEARCH EFFORT SOUGHT TO DEFINE HOW TO IDENTIFY SUCH CELLS IN A FIRST STEP TOWARD REVERSING LATENCY AND ELIMINATING HIV RESERVOIRS. IT WAS KNOWN THAT CERTAIN PROTEINS THAT INHIBIT THE ABILITY TO ACTIVATE A T CELL, THE "IMMUNE CHECKPOINT PROTEINS," CONCURRENTLY BLOCK THE ABILITY TO CONVERT THAT CELL FROM A LATENT TO AN ACTIVE STATE OF HIV GROWTH, WHICH IS TYPICALLY NECESSARY FOR THE CELLS TO BECOME TARGETS FOR ELIMINATION. MORE CHARACTERIZATION OF LATENTLY INFECTED CELLS WAS NEEDED. THE AUTHORS COLLECTED LARGE AMOUNTS OF CD4+ T CELLS FROM 21 PEOPLE ON ART AND OBTAINED LYMPH NODE BIOPSIES FROM EIGHT OF THEM. THOSE CELLS IN BLOOD AND TISSUE CONTAINING TWO IMMUNE PROTEINS, PD1 AND CTLA4, PROVED TO CONTAIN MORE LATENT VIRUS THAN THEIR COUNTERPARTS LACKING THOSE PROTEINS. THE RESEARCHERS WENT ON TO IDENTIFY SPECIFIC GENES LINKED TO PD1 AND CTLA4 THAT APPEARED RESPONSIBLE FOR MAINTAINING THAT LATENT STATE. AUTHORS OF THIS PAPER, PUBLISHED IN CELL REPORTS MEDICINE, INCLUDE AMFAR GRANTEES AT UCSF, UNIVERSITY OF MELBOURNE, AND THE UNIVERSITY OF MONTREAL. SOLVING THE PUZZLE OF POST-TREATMENT CONTROL PUBLISHED IN THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, AMFAR GRANTEES XU YU, MD, OF THE RAGON INSTITUTE OF MGH, MIT AND HARVARD, AND JONATHAN LI, MD, OF BRIGHAM AND WOMEN'S HOSPITAL IN BOSTON, AND THEIR COLLEAGUES INVESTIGATED WHY A RARE GROUP OF INDIVIDUALS, KNOWN AS POST-TREATMENT CONTROLLERS (PTCS), CAN SUPPRESS HIV REBOUND TO VERY LOW LEVELS FOR PROLONGED PERIODS AFTER ART WITHDRAWAL. RESEARCHERS IDENTIFIED 22 PTCS FROM EIGHT STUDIES OF SUPERVISED ART WITHDRAWAL, ALONG WITH 37 POST-TREATMENT NON-CONTROLLERS (NCS) WHO EXPERIENCED RAPID VIRAL REBOUND AFTER STOPPING ART. PTCS DEMONSTRATED A UNIQUE IMMUNOLOGIC PROFILE. THEY HAD LOWER LEVELS OF CD4 AND CD8 T-CELL ACTIVATION, LOWER CD4 CELL EXHAUSTION, AND MORE ROBUST NATURAL KILLER (NK) CELL FUNCTION AND CD4 T-CELL RESPONSES TO CERTAIN HIV PROTEINS. THESE PROCESSES WERE LINKED TO A STABLE RESERVOIR OF LATENTLY INFECTED CELLS. SURPRISINGLY, PTCS HAD LOWER LEVELS OF INFLAMMATION, IN MARKED CONTRAST TO "ELITE CONTROLLERS" WHO SUPPRESS HIV DESPITE NEVER HAVING RECEIVED ART, WHICH IS ASSOCIATED WITH INCREASED INFLAMMATION.
FORM 990, PART III, LINE 4A	RESEARCH FOR HIS GROUNDBREAKING WORK ON MRNA, VETERAN HIV RESEARCHER AND AMFAR GRANTEE DR. DREW WEISSMAN OF THE UNIVERSITY OF PENNSYLVANIA, ALONG WITH COLLABORATOR DR. KATALIN KARIK, WAS AWARDED THE 2023 NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE. DR. WEISSMAN DEVELOPED A WORKAROUND TO THE LONG-KNOWN LIMITATIONS OF MRNA AS A VACCINE AND THERAPEUTIC CANDIDATE - IT'S FRAGILE AND, WHEN MRNA IS DELIVERED TO CELLS, IT INDUCES A DANGEROUS AND POTENTIALLY LETHAL IMMUNE RESPONSE - BY WRAPPING THE MRNA IN SPECIALIZED LIPID SHELLS, KNOWN AS NANOPARTICLES OR "FAT BUBBLES." DOING SO PROTECTS MRNA FROM BEING RAPIDLY DISSOLVED IN TISSUE AND FACILITATES ITS ENTRY INTO IMMUNE CELLS, A STRATEGY THAT PROVED INSTRUMENTAL IN THE DEVELOPMENT OF EFFECTIVE VACCINES FOR COVID-19. CURRENTLY, AS A PRINCIPAL INVESTIGATOR ON A MULTI-YEAR AMFAR-FUNDED RESEARCH PROJECT AIMED AT DEVELOPING AND TESTING A COMPLEX GENE THERAPY APPROACH TO CURING HIV (SEE COMBINATION STRATEGY BELOW), DR. WEISSMAN IS USING MRNA TECHNOLOGY TO TARGET THE HIV RESERVOIR, THE MAIN BARRIER TO A CURE. THROUGHOUT FY2023, AMFAR'S RESEARCH PROGRAM SUPPORTED 31 RESEARCH TEAMS INVOLVING 120 SCIENTISTS THROUGH GRANTS AND FELLOWSHIPS. AMFAR CURE TRIAL SHOWS PROOF OF CONCEPT IN FEBRUARY 2023, FINDINGS FROM 12 AMFAR-FUNDED RESEARCH PROJECTS WERE PRESENTED AT THE 30TH ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI). MOST IMPORTANTLY, RESEARCHERS AT THE AMFAR INSTITUTE FOR HIV CURE RESEARCH AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SHARED THE NEWS THAT THEIR COMBINATION IMMUNOTHERAPY APPROACH TO CURING HIV SHOWS PROMISE. THE ONGOING TRIAL, WHICH HAS ENROLLED 10 PARTICIPANTS WHOSE HIV WAS WELL CONTROLLED BY ANTIRETROVIRAL THERAPY (ART), IS TESTING A COMBINATION OF AGENTS IN AN EFFORT TO INDUCE POST-TREATMENT CONTROL IN PEOPLE LIVING WITH HIV. POST-TREATMENT CONTROL WOULD ALLOW PEOPLE LIVING WITH HIV TO SAFELY DISCONTINUE ART AND THUS AVOID ITS ASSOCIATED COSTS, TOXICITIES, AND SIDE EFFECTS. THE MAJORITY OF PARTICIPANTS IN THE PHASE 1/2 SINGLE-ARM STUDY, WHICH RECEIVED ADDITIONAL SUPPORT FROM GILEAD SCIENCES, SHOWED EVIDENCE OF VIROLOGIC CONTROL AFTER ART WAS STOPPED. WHILE ALMOST ALL SHOWED SIGNS THAT THE VIRUS PERSISTED, SEVEN OF THE 10 DID NOT REBOUND IN THE USUAL WAY, WHERE A RAPID BURST OF UNCONTROLLED VIRAL GROWTH WOULD OTHERWISE BE EXPECTED. THIS STUDY ESTABLISHED PROOF OF CONCEPT THAT COMBINATION IMMUNOTHERAPY MAY INDUCE POST-TREATMENT CONTROL BY ALTERING FACETS OF THE VIRUS OR THE IMMUNE RESPONSE TO IT AS PART OF A CURE INTERVENTION. INVESTIGATING ALLOGENEIC IMMUNITY STEM CELL TRANSPLANTATION USING DONOR CELLS WITH A CCR5 DELTA32 MUTATION IS CURRENTLY THE ONLY APPROACH PROVEN TO ERADICATE THE HIV RESERVOIR AND THEREBY EFFECT A CURE IN PEOPLE LIVING WITH HIV. BUT THE MUTATION IS RARE AND THIS HIGH-RISK PROCEDURE IS NOT SCALABLE. AS RESEARCHERS STUDY THE INDIVIDUAL MECHANISMS BY WHICH THE TRANSPLANT CURE METHOD WORKS, ONE OPEN ISSUE IS THE EXTENT TO WHICH CCR5-DEFICIENT DONOR STEM CELLS ARE REQUIRED TO DRIVE A TRANSPLANT-RELATED HIV CURE, AS OPPOSED TO SO-CALLED "ALLOGENEIC IMMUNITY" DRIVEN BY THE DONOR T CELLS REGARDLESS OF THEIR CCR5 STATUS. IN A STUDY LED BY AMFAR GRANTEE DR. JONAH SACHA OF OREGON HEALTH & SCIENCE UNIVERSITY, FOUR MONKEYS WERE INFECTED WITH SIV, THE SIMIAN EQUIVALENT OF HIV, TREATED WITH ART UNTIL VIRAL SUPPRESSION, AND THEN UNDERWENT A STEM CELL TRANSPLANT. SOME 22.5 YEARS LATER, ART WAS STOPPED AND LEVELS OF ACTIVE AND LATENT VIRUS IN BLOOD AND TISSUES WERE EXAMINED. ALL FOUR ANIMALS HAD A 1,000-FOLD REDUCTION OF THE VIRAL RESERVOIR IN BLOOD, LYMPH NODES, AND INTESTINES. THE ONE ANIMAL THAT ACHIEVED A COMPLETE RECONSTITUTION WITH DONOR CELLS HAS NO DETECTABLE VIRUS AND APPEARS TO HAVE BEEN CURED. THE RESEARCHERS SUGGEST THAT ALLOGENEIC IMMUNITY CAN INDEED ELIMINATE HIV RESERVOIRS AND THAT HARNESSING SUCH IMMUNITY OUTSIDE OF TRANSPLANTATION MAY DEVELOP NEW APPROACHES TO CURING HIV THAT CAN BE MORE BROADLY EFFECTIVE. SUPPORTING CUTTING-EDGE RESEARCH AMFAR AWARDS TWO MAIN TYPES OF GRANTS: TARGET GRANTS SUPPORT RESEARCH INTO HIV CURE INTERVENTIONS AIMED AT ELIMINATING INFECTED CELLS OR PROVIRUS; AND ARCHE (AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION) GRANTS SUPPORT COLLABORATIVE RESEARCH INITIATIVES AIMED AT CURING HIV. ARCHE GRANTS COMBINATIONS STRATEGY A LEADING GENE THERAPY RESEARCHER AND A PAST PRESIDENT OF THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY, HILDEGARD BNING, PHD, OF THE HANNOVER MEDICAL SCHOOL IN GERMANY, IS CO-PRINCIPAL INVESTIGATOR OF AN AMFAR-FUNDED CONSORTIUM OF GENE THERAPY SCIENTISTS WORKING TO DEVELOP A COMPLEX, THREE-PRONGED ATTACK ON THE HIV RESERVOIR. RECENT NOBEL PRIZE WINNER DR. DREW WEISSMAN IS ALSO A PRINCIPAL INVESTIGATOR ON THE STUDY. THE STRATEGY INVOLVES: ANTIBODIES CAPABLE OF NEUTRALIZING A BROAD RANGE OF HIV SUBTYPES (BNABS), CAR STEM CELLS, AND MOLECULAR SCISSORS TARGETING THE VIRUS. WITH A GRANT OF $1.3 MILLION, DR. BNING AND HER COLLABORATORS ARE TESTING THE STRATEGY IN AN ANIMAL STUDY AND WILL DETERMINE THE EFFICACY OF EACH INTERVENTION, ALONE AND IN COMBINATION. TARGET GRANTS GENE THERAPY SHARON LEWIN, MD, PHD, OF THE UNIVERSITY OF MELBOURNE, WAS AWARDED $480,000 FOR A STUDY USING THE MRNA ENCASED IN A LIPID NANOPARTICLE DELIVERY SYSTEM. THIS MRNA VEHICLE WILL TRANSPORT A GENE-EDITING TOOL TO HIV-INFECTED RESERVOIR CELLS IN ORDER TO REACTIVATE THEM, MAKING THEM A TARGET FOR ERADICATION. NO INTERVENTION HAS SO FAR PROVEN POWERFUL ENOUGH TO FORCE HIV-INFECTED CELLS TO START REPLICATING IN A WAY THAT MAKES THEM VULNERABLE TO CELL DEATH. DR. LEWIN IS USING A FORM OF THE CRISPR-CAS GENE-EDITING SYSTEM MODIFIED TO BIND TO THE VIRAL DNA AND DIRECTLY FORCE THE VIRUS TO START REPLICATING. HANS-PETER KIEM, MD, PHD, OF THE FRED HUTCHINSON CANCER CENTER, IN SEATTLE, WASHINGTON, WAS AWARDED $480,000 TO DEVELOP A "PORTABLE GENE THERAPY TREATMENT" WITHIN A PATIENT'S BODY AS PART OF AN HIV CURE INTERVENTION THAT DOES NOT RELY ON A STEM CELL TRANSPLANT. DR. KIEM IS TESTING ENGINEERED VIRUS-LIKE PARTICLES THAT CAN DELIVER GENE-EDITING ENZYMES DIRECTLY TO THE BLOOD, LIVER, BRAIN, ETC., IN AN ANIMAL MODEL IN AN ATTEMPT TO DISRUPT THE CCR5 RECEPTOR IN BLOOD-FORMING STEM CELLS AND MAKE THEM RESISTANT TO HIV INFECTION. CAR T CELLS THOUGH SUCCESSFUL IN SOME CANCER TREATMENTS, GENETICALLY ENGINEERED CAR T CELLS HAVE NOT BEEN EFFECTIVE AGAINST HIV FOR SEVERAL REASONS: CAR T CELLS ARE THEMSELVES VULNERABLE TO HIV INFECTION, AND, EVEN WHEN THEY REMAIN UNINFECTED, THEY CANNOT ACHIEVE BROAD ENOUGH COVERAGE OR PERSIST LONG ENOUGH TO BE EFFECTIVE. MARTIN TOLSTRUP, PHD, OF AARHUS UNIVERSITY IN DENMARK, IS USING HIS GRANT OF $477,000 TO ATTEMPT TO OVERCOME THESE OBSTACLES USING CRISPR GENE-EDITING TECHNOLOGY AND OTHER STRATEGIES. AWARDED A GRANT IN THE AMOUNT OF $120,000, DANIEL CLAIBORNE OF THE WISTAR INSTITUTE IN PHILADELPHIA WILL ALSO ATTEMPT TO OPTIMIZE A CAR T CELL APPROACH FOR USE AGAINST HIV BY FIRST ENGINEERING A PANEL OF CARS TARGETING NON-TRADITIONAL PORTIONS OF THE HIV ENVELOPE AND THEN TESTING THEM IN A MOUSE MODEL. NATURAL KILLER CELLS DR. ANNA HEARPS OF THE BURNET INSTITUTE IN MELBOURNE, AUSTRALIA, WAS AWARDED $106,088 TO DEVELOP A MEANS OF KILLING HIV-INFECTED MACROPHAGE CELLS. MACROPHAGES ARE LONG-LIVED CELLS THAT ARE HIGHLY RESISTANT TO KILLING BY THE IMMUNE SYSTEM EVEN WHEN INFECTED. DR. HEARPS PLANS TO DISCOVER WHICH ANTI-HIV ANTIBODIES BEST RECOGNIZE HIV-INFECTED MACROPHAGES. SHE ALSO AIMS TO IDENTIFY THE MOST LETHAL SUBSET OF NATURAL KILLER (NK) CELLS, WHICH WILL BE RECRUITED BY THE ANTIBODIES TO KILL THE MACROPHAGES AND FORM PART OF AN IMMUNOTHERAPY TO CURE HIV. DR. LUIS MONTANER OF THE WISTAR INSTITUTE WAS AWARDED $372,662 TO BUILD ON RECENT ADVANCES IN CANCER RESEARCH TO GENERATE GENETICALLY MODIFIED NK CELLS THAT ARE OPTIMALLY DESIGNED TO KILL HIV-INFECTED CELLS. HE IS ENGINEERING THE NK CELLS TO BIND TO ANTIBODIES THAT EFFECTIVELY SEEK OUT HIV-INFECTED CELLS AND MODIFYING THE ANTIBODIES TO BECOME MORE EFFECTIVE AT INDUCING DEATH OF INFECTED CELLS. DR. PAMELA SKINNER OF THE UNIVERSITY OF MINNESOTA ALSO PLANS TO ENLIST ENGINEERED NK CELLS TO TARGET THE HIV RESERVOIR. WHILE CYTOTOXIC T CELLS AND NK CELLS ARE SOME OF THE MOST EFFECTIVE KILLERS OF THE IMMUNE SYSTEM, THEY ARE INEFFECTIVE AGAINST THE HIV RESERVOIR IN PART BECAUSE THEY DO NOT EASILY ACCESS THE REGIONS OF THE LYMPH NODE WHERE A MAJOR RESERVOIR PERSISTS. WITH A $480,000 GRANT, DR. SKINNER IS ENGINEERING CAR-T AND CAR-NK CELLS TO ZERO IN ON THE LYMPH NODES TO ENHANCE THEIR CHANCES OF SUCCESS. SHE IS ALSO MODIFYING THEM TO OVERCOME THE EXHAUSTION TO WHICH IMMUNE CELLS ARE PRONE AND TO RESIST BECOMING HIV-INFECTED CELLS THEMSELVES. MATHILDE KRIM FELLOWSHIPS STEVEN DE TAEYE, PHD, OF THE UNIVERSITY OF AMSTERDAM IN THE NETHERLANDS, RECEIVED A 2023 MATHILDE KRIM FELLOWSHIP IN BIOMEDICAL RESEARCH TO SUPPORT A TWO-YEAR STUDY USING ANTIBODY CONJUGATES AS A POTENTIAL CURE FOR HIV.
FORM 990, PART III, LINE 4B	INTERNATIONAL AIDS CONFERENCE ON HIV SCIENCE AND OTHER CONFERENCES TREAT ASIA HAD A STRONG PRESENCE AT IAS 2023. DR. SOHN GAVE MULTIPLE PRESENTATIONS, INCLUDING ONE AT THE 15TH INTERNATIONAL WORKSHOP ON HIV & PEDIATRICS, WHICH PRECEDED THE MAIN CONFERENCE. DR. JEREMY ROSS, TREAT ASIA'S DIRECTOR OF RESEARCH, AND NUMEROUS TREAT ASIA PARTNER INVESTIGATORS AND AFFILIATES ALSO PRESENTED AT THE CONFERENCE. TREAT ASIA ALSO PARTICIPATED IN THE HIV GLASGOW 2022 CONFERENCE IN OCTOBER; THE 25TH BANGKOK INTERNATIONAL SYMPOSIUM ON HIV MEDICINE IN JANUARY 2023; THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) 2023 AND THE GLOBAL IEDEA MEETING, BOTH IN SEATTLE, WASHINGTON, IN FEBRUARY; THE 25TH INTERNATIONAL WORKSHOP ON HIV AND HEPATITIS OBSERVATIONAL DATABASES (IWHOD 2023) IN ATHENS GREECE IN MARCH; APACC 2023, AND ITS PRECONFERENCE, HIV CASCADE OF CARE: CLOSING THE GAP, IN SINGAPORE IN JUNE; THE FOGARTY INTERNATIONAL CENTER (FIC) HIV RESEARCH TRAINING NETWORK HYBRID MEETING IN JULY; AND THE 9TH WHO GLOBAL VALIDATION ADVISORY COMMITTEE (GVAC) MEETING FOR ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION OF HIV, SYPHILIS, AND HEPATITIS B VIRUS IN GENEVA, SWITZERLAND, IN AUGUST. PUBLICATIONS ALONG WITH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC REGION, TREAT ASIA PUBLISHED AN ISSUE BRIEF TITLED HEPATITIS B: A HIDDEN PUBLIC HEALTH EMERGENCY IN THE ASIA-PACIFIC; A POLICY BRIEF CALLING FOR EXPANDED ACCESS TO PEDIATRIC DOLUTEGRAVIR; AN INFORMATION BRIEF ABOUT COMMUNITY-LED MONITORING PROPOSALS FOR THE GLOBAL FUND; AND A COMMENTARY IN THE LANCET GASTROENTEROLOGY AND HEPATOLOGY ON HEPATITIS B AND PREP FOR HIV PREVENTION. TREAT ASIA ALSO CO-AUTHORED HIV CARE CONTINUUM & BEYOND: A NEW ERA FOR ASIA, WHICH ASSESSED TO WHAT EXTENT LOCAL INITIATIVES HAVE STRENGTHENED THE CARE CONTINUUM AND DETAILED HOW COMMUNITY ENGAGEMENT HAS PLAYED A VITAL ROLE IN DEVELOPING AND DELIVERING PERSON-CENTERED INTERVENTIONS. IN ADDITION, TREAT ASIA'S PROGRAM MANAGER, GITEN KHWAIRAKPAM, SUPPORTED HEPATITIS AUSTRALIA ON A GLOBAL PRIORITY STATEMENT ON THE INTEGRATION OF HEPATITIS B RESPONSES IN HARM REDUCTION PROGRAMS.
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE.
FORM 990, PART VI, SECTION B, LINE 12C	EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY.
FORM 990, PART VI, SECTION B, LINE 15	AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN AUGUST OF 2020 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED ANNUALLY BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS.
FORM 990, PART VI, SECTION C, LINE 19	AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED WILL BE PROVIDED AT MANAGEMENT'S DISCRETION.
FORM 990, PART XI, LINE 9:	OVERACCRUAL OF GRANT EXPENSE 329,258. WRITE OFF OF UNCOLLECTIBLE PLEDGES -555,421.
FORM 990, PART XII, LINE 2C:	THE ORGANIZATION HAS A COMMITTEE THAT IS RESPONSIBLE FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.
PART IX, LINES 1-3	THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.